Furthermore, the use of B cell depletion with rituximab (targeting CD20+ B cells, including late pre-B lymphocytes, B cells but not terminally differentiated plasmablasts and plasma cells) or belimumab (anti-B-cell activating factor (BAFF)/B-lymphocyte stimulator (BLyS)) alone or in combination with CPM has been discussed to treat NP-SLE. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.